Literature DB >> 1571442

Interactions of fluoroquinolones with other drugs: mechanisms, variability, clinical significance, and management.

J M Radandt1, C R Marchbanks, M N Dudley.   

Abstract

Several important interactions of fluoroquinolones with other drugs have been reported in the literature. The absorption of all fluoroquinolones is almost entirely inhibited by concomitant administration of di- and trivalent cations, such as aluminum and magnesium contained in antacids. The inhibition of absorption can be significant and can potentially lead to the failure of treatment, even when fluoroquinolone doses are separated from antacid doses by hours. Certain isozymes of the cytochrome P-450 system are selectively inhibited by some fluoroquinolones. The metabolism of theophylline and caffeine is inhibited by enoxacin and ciprofloxacin such that the dosage of theophylline may need to be reduced in order to avoid toxicity. In contrast, ofloxacin and norfloxacin cause less inhibition of the metabolism of these compounds, and reduction of the theophylline dosage is not routinely required. Evidence regarding the effect of fluoroquinolones on the disposition of other drugs known to be metabolized, such as warfarin and cyclosporine, is inconclusive. In summary, the safe and effective use of fluoroquinolone antibiotics requires careful consideration of concomitant drug therapy.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1571442     DOI: 10.1093/clinids/14.1.272

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  26 in total

1.  Case report: prescribing caution. When a simple disease isn't so simple.

Authors:  Cremona Ticea; James M Wright
Journal:  Can Fam Physician       Date:  2003-02       Impact factor: 3.275

2.  Pharmacokinetics of gatifloxacin and interaction with an antacid containing aluminum and magnesium.

Authors:  S Lober; S Ziege; M Rau; G Schreiber; A Mignot; P Koeppe; H Lode
Journal:  Antimicrob Agents Chemother       Date:  1999-05       Impact factor: 5.191

Review 3.  Clinically significant drug interactions with antacids: an update.

Authors:  Ryuichi Ogawa; Hirotoshi Echizen
Journal:  Drugs       Date:  2011-10-01       Impact factor: 9.546

Review 4.  Clinically significant interactions with drugs used in the treatment of tuberculosis.

Authors:  W W Yew
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

Review 5.  Important drug interactions in dermatology.

Authors:  T C Roos; H F Merk
Journal:  Drugs       Date:  2000-02       Impact factor: 9.546

6.  Pharmacokinetic evaluation of oral levofloxacin in human immunodeficiency virus-infected subjects receiving concomitant antiretroviral therapy.

Authors:  P Villani; P Viale; L Signorini; B Cadeo; F Marchetti; A Villani; C Fiocchi; M B Regazzi; G Carosi
Journal:  Antimicrob Agents Chemother       Date:  2001-07       Impact factor: 5.191

7.  Effects of antacid on absorption and excretion of new quinolones.

Authors:  K Shiba; M Sakamoto; Y Nakazawa; O Sakai
Journal:  Drugs       Date:  1995       Impact factor: 9.546

8.  Levofloxacin in patients with severe respiratory tract infection.

Authors:  S Odagiri
Journal:  Drugs       Date:  1995       Impact factor: 9.546

9.  Inhibitory effect of ofloxacin on acute exacerbations of chronic respiratory tract infections in comparison with erythromycin.

Authors:  S Kawahara; Y Watanabe; Y Matsuka; T Sato; K Takahashi
Journal:  Drugs       Date:  1995       Impact factor: 9.546

Review 10.  Treatment of Legionnaires' disease. Current recommendations.

Authors:  J Roig; A Carreres; C Domingo
Journal:  Drugs       Date:  1993-07       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.